Presentation Information

[P077]Production of thermostable Leishmanin antigen and following investigation of memory immune response using human PBMC.

○Shara Bakytbek1,2,3, Shin-Ichi Inoue4, Farzaneh Valanezhad1,2,3, Ranadhir Dey5, Jalal Alshaweesh6, Risa Nakamura1,2,3, Swarnendu Kaviraj7, Shaden Kamhawi8, Jesus G. Valenzuela8, Sanjay Singh7, Abhay R. Satoskar9, Sreenivas Gannavaram10, Hira L. Nakhasi10, Greg Matlashewski11, Shinjiro Hamano1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Division of Immunology, Nagasaki University, Nagasaki City, Nagasaki (Japan), 5. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD (United States of America), 6. Division of Malaria Immunology, Department of Microbiology and Immunology, Institute of Medical Science (IMSUT), Tokyo University (Japan), 7. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra (India), 8. Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, 20852 (United States of America), 9. Department of Pathology and Microbiology, Ohio State University, Columbus, OH (United States of America), 10. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD (United States of America), 11. Department of Microbiology and Immunology, McGill University, Montreal, QC (Canada))

Password required to view


Comment

To browse or post comments, you must log in.Log in